[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641607":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":39,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Medtronic Neurovascular Clinical Affairs","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","Device: Mechanical Thrombectomy","Index stroke procedure and follow-up visits up to 90 days post index procedure",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Stephanie Salisbury","CONTACT","612-979-7251","rs.recanovaregistry@medtronic.com",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Buffalo General Medical Center","RECRUITING","Buffalo","New York","14203","United States","US",{"type":29,"coordinates":30},"Point",[31,32],-78.87837,42.88645,{"lat":32,"lon":31},[35],{"name":36,"role":16,"phone":37,"phoneExt":7,"email":38},"Jason Davies, MD","716-218-1000","jdavies@ubns.com",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100641607","real-world-clinical-evaulation-of-medtronic-neurovascular-products-for-acute-ischemic-stroke-recanova-registry-100641607",false,"NCT07599904","REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)","RECANOVA","Inclusion Criteria:\n\n1. Patient or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements.\n2. Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\\* during treatment for acute ischemic stroke.\n3. Participant is 18 years of age or older.\n\nExclusion Criteria:\n\n1. Participant who may be unable to complete follow-up within the registry.\n2. Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.\n3. Participant is currently enrolled in, or plans to enroll in, any concurrent drug\u002Fdevice study that may confound the study results based on Principal Investigator's discretion.","ALL","18 Years",{"count":51,"type":52},1500,"ESTIMATED","90 Days","OBSERVATIONAL","Post-Market Registry",[57],"Acute Ischemic Stroke","2026-06-16",{"date":60,"type":61},"2026-06-18","ACTUAL",{"date":63,"type":52},"2026-06",{"date":65,"type":52},"2031-07",{"name":5,"class":6},1]